TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06592742

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary rehabilitation (alone)
Description: The Pulmonary Rehabilitation (PR) program for the control group includes daily aerobic exercises such as treadmill walking or cycling for 20-30 minutes at moderate intensity, tailored to improve cardiovascular fitness and respiratory function. Strength training focuses on major muscle groups with resistance exercises lasting 15-20 minutes, promoting muscle strength and endurance. Airway clearance techniques are performed for 15-20 minutes daily, using methods like chest physiotherapy or positive expiratory pressure (PEP) to clear mucus from the lungs. Breathing exercises, including diaphragmatic and pursed-lip breathing, are practiced for 10-15 minutes to improve breathing efficiency. Participants also receive education on disease management and nutritional support to meet caloric needs.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention group (PR + PMR)
Description: The intervention group will follow a Pulmonary Rehabilitation (PR) program combined with Progressive Muscle Relaxation (PMR). Daily aerobic exercises like treadmill walking or cycling will be performed for 20-30 minutes at moderate intensity, improving cardiovascular fitness and lung function. Strength training for major muscle groups will be included, with 15-20 minutes of resistance exercises to enhance muscle strength. Airway clearance techniques, such as chest physiotherapy or PEP, will help clear mucus from the lungs in daily 15-20 minute sessions. Breathing exercises, including diaphragmatic and pursed-lip breathing, will be practiced for 10-15 minutes to improve breathing efficiency. The PMR component involves daily 20-30 minute guided sessions to reduce stress and anxiety through muscle relaxation techniques.
Study: NCT06616610

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention with the Mobility Platform
Description: The experimental arm receives the Intervention with Mobility Platform that is a focus of the study. It aims to analyze the impact of a single-button-operated mobility platform on reaction times and keypress patterns in children with severe disabilities.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intervention with Traditional Therapy
Description: The traditional cause-effect therapies use an animated cartoon video that frequently pauses so that the children have to press an adapted button to continue watching it.
Study: NCT05304871

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefazolin
Description: infusion

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: infusion
Study: NCT06376916

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Sulfate 2 G
Description: Magnesium Sulfate 2g for the treatment of atrial fibrillation or atrial flutter with rapid ventricular response (AFF RVR)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Sulfate 4 G
Description: Magnesium Sulfate 4g for the treatment of atrial fibrillation or atrial flutter with rapid ventricular response (AFF RVR)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: The control group will receive a bolus of normal saline of the same volume and infused over 15 minutes.
Study: NCT05454514

Intervention type: DEVICE
Group type: OTHER
Intervention: HiDO medication adherence platform
Description: The HiDO medication adherence platform will be shipped directly to the home of record of each participant. The Primary Endpoint is medication adherence as assessed by remote observation through the HiDO device at 90 days.

Intervention type: DEVICE
Group type: OTHER
Intervention: Automated Medication Platform with Video Observation
Description: There is no drug intervention. The device elicits increases adherence of medications.
Study: NCT06127173

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Positive End Expiratory Pressure PEEP
Description: children will receive different levels of PEEP during induction of anesthesia

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Positive End Expiratory Pressure PEEP
Description: children will receive different levels of PEEP during induction of anesthesia

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Positive End Expiratory Pressure PEEP
Description: children will receive different levels of PEEP during induction of anesthesia
Study: NCT05849090

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cephalosporin or clindamycin/vancomycin antibiotics..
Description: Antibiotics: Cephalosporin, 2-grams, intravenous (IV), or clindamycin (900mg) / vancomycin (20mg/kg), intravenous (IV).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin and Tobramycin antibiotics.
Description: Vancomycin (1 gram) and tobramycin (1.2 grams).
Study: NCT06331598

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: A dose of 1680 mg atezolizumab will be administered intravenously on Day 1 of each 28-day cycle for a total of 12 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: A dose of 1680 mg atezolizumab will be administered intravenously on Day 1 of each 28-day cycle for a total of 12 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiragolumab
Description: A dose of 840 mg tiragolumab will be administered intravenously on Day 1 of each 28-day cycle for a total of 12 cycles.
Study: NCT05513703

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Telisotuzumab Vedotin
Description: Intravenous (IV) Infusion
Study: NCT05599126

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mianserin
Description: Subjects were required to take mianserin regularly during the study period, with the effective dose being taken orally once a night before bedtime.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lorazepam
Description: Subjects were required to take lorazepam regularly during the study period, with the effective dose being taken orally once a night before bedtime.
Study: NCT05454514

Intervention type: OTHER
Group type: OTHER
Intervention: Time on Task
Description: Other Endpoints include Time on Task for initial registration, first click testing, facial recognition setup, medication administration, number and type of critical and non-critical errors and error-free rate, System Usability Scale (SUS), and Net Promoter Score.
Study: NCT05319730

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: 80-100 mg/m2 IV infusion, administered on days 1, 8, and 15 of every 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 80-100 mg/m2 IV infusion, administered on days 1, 8, and 15 of every 28-day cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Description: 180 mg/m2 IV infusion, administered on day 1 of every 14-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 180 mg/m2 IV infusion, administered on day 1 of every 14-day cycle.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg IV infusion, administered every Q3W.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg IV infusion, administered every Q3W.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MK-4830
Description: 800 mg IV infusion, administered Q3W up to 35 infusions.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MK-4830
Description: 800 mg IV infusion, administered Q3W up to 35 infusions.
Study: NCT06315400

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ingavirin®
Description: 60 mg/day for 5 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 capsule/day for 5 days
Study: NCT05319730

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: 20 mg oral administration every day.
Study: NCT04720781

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vonoprazan
Description: Vonoprazan (20mg/day) is prescribed for 4 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Esomeprazole
Description: esomeprazole (20mg/day)
Study: NCT05969236

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MDI-1228_mesylate Ophthalmic Solution
Description: MDI-1228_mesylate Ophthalmic Solution includes 2 strengths:~* 0.1% (0.4 mL \[0.4 mg\] free base)~* 0.3% (0.4 mL \[1.2 mg\] free base)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The components employed in the placebo formulation are the same as those used for the active formulation except MDI-1228_mesylate is absent.
Study: NCT05591001

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ketamine and dexmeditomidine combination
Description: Dexmedetomidine( 0.4 -0.6 μg/.kg /.hr)) ketamine,( 1 -2m/.kg/.hr) infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: propofol (100 ug /kg/min) infusion
Study: NCT05593042

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: CoronaVac®
Description: The active ingredient is the SARS-CoV-2 virus (CZ02 strain, ancestral) grown in Vero cells and inactivated, in aluminum hydroxide. The vaccine is preservative-free, and it is packed in pre-load syringes (0.5 mL) with 600 SU/0.5mL of inactivated SARS-CoV-2.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Omicron Vaccine
Description: An experimental intervention consisting of a booster dose of an inactivated Omicron variant vaccine.~The active ingredient is the SARS-CoV-2 virus (Omicron variant) grown in Vero cells and inactivated, in aluminum hydroxide. The vaccine is preservative-free, packed in a pre-load syringe, and contains one dose (0.5mL) of 1200 SU of inactivated SARS-CoV-2 Omicron variant.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Omicron Vaccine
Description: An experimental intervention consisting of a booster dose of an inactivated Omicron variant vaccine.~The active ingredient is the SARS-CoV-2 virus (Omicron variant) grown in Vero cells and inactivated, in aluminum hydroxide. The vaccine is preservative-free, packed in a pre-load syringe, and contains one dose (0.5mL) of 1200 SU of inactivated SARS-CoV-2 Omicron variant.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent Vaccine
Description: An experimental intervention consisting of a booster dose of an inactivated trivalent (CZ02 strain, ancestral, Delta, and Omicron variants) variant vaccine.~The active ingredient is the SARS-CoV-2 virus (CZ02 strain, ancestral, Delta, and Omicron variants) grown in Vero cells and inactivated, in aluminum hydroxide. The vaccine is preservative-free, and it is packed in a pre-load syringe containing one dose (0.5mL) (1200 SU of inactivated SARS-CoV-2 WT, 1200 SU of inactivated SARS-CoV-2 Delta variant, and 1200 SU of inactivated SARS-CoV-2 Omicron variant).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent Vaccine
Description: An experimental intervention consisting of a booster dose of an inactivated trivalent (CZ02 strain, ancestral, Delta, and Omicron variants) variant vaccine.~The active ingredient is the SARS-CoV-2 virus (CZ02 strain, ancestral, Delta, and Omicron variants) grown in Vero cells and inactivated, in aluminum hydroxide. The vaccine is preservative-free, and it is packed in a pre-load syringe containing one dose (0.5mL) (1200 SU of inactivated SARS-CoV-2 WT, 1200 SU of inactivated SARS-CoV-2 Delta variant, and 1200 SU of inactivated SARS-CoV-2 Omicron variant).
Study: NCT06616363

Intervention type: DIAGNOSTIC_TEST
Intervention: A fMRI scan
Description: • Participants will complete a fMRI scan without contrast and complete a looming animacy threat task; participants judge the valence of images via button press as they perceive the image.

Intervention type: DIAGNOSTIC_TEST
Intervention: A fMRI scan
Description: • Participants will complete a fMRI scan without contrast and complete a looming animacy threat task; participants judge the valence of images via button press as they perceive the image.
Study: NCT06616259

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mCapOX plus Cetuximab
Description: mCapOX plus Cetuximab Induction therapy：Capecitabine 1000mg/m2 po, bid, D1-7 + Oxaliplatin ivgtt 85mg/m2, D1 + Cetuximab ivgtt 500mg/m2, D1; Q2W. Up to 12 cycle, if no progression, enter maintenance therapy.~Maintenance therapy: Capecitabine 1000mg/m2 po, bid, D1-7 + Cetuximab ivgtt 500mg/m2, D1; Q2W. Until disease progression or toxicity is not tolerated. Cetuximab can be discontinued alone if not tolerated.~Treatment after progression of maintenance therapy: Participants have the option to accept reintroducing the first-line induction chemotherapy regimen (mCapOx or mFOLFOX6 in combination with cetuximab) or accept second-line therapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mFOLFOX6 plus Cetuximab
Description: mFOLFOX6 plus Cetuximab Induction therapy：Oxaliplatin ivgtt 85mg/m2, D1 + Leucovorin ivgtt 400mg/m2, D1 + Fluorouracil iv bolus 400mg/m2, D1 + Fluorouracil 2400mg/m2 continuous infusion for 46-48h + Cetuximab ivgtt 500mg/m2, D1; Q2W. Up to 12 cycle, if no progression, enter maintenance therapy.~Maintenance therapy: Capecitabine 1000mg/m2 po, bid, D1-7 + Cetuximab ivgtt 500mg/m2, D1; Q2W. Until disease progression or toxicity is not tolerated. Cetuximab can be discontinued alone if not tolerated.~Treatment after progression of maintenance therapy: Participants have the option to accept reintroducing the first-line induction chemotherapy regimen (mCapOx or mFOLFOX6 in combination with cetuximab) or accept second-line therapy.
Study: NCT06617000

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SCG101
Description: Infusion of HBsAg-specific TCR autologous T cells at assigned dose levels.
Study: NCT06617507

Intervention type: OTHER
Intervention: Group 1
Description: The Modified Ashworth Scale (MAS), The Gillette Functional Assessment Questionnaire (FAQ) and The Edinburgh Visual Gait Score (EVGS) were applied to the participants.
Study: NCT06617416

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cadonilimab (AK104)
Description: AK104 ivgtt Q3W

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sugemalimab
Description: 1200mg Q3W
Study: NCT06678685

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: .spironolactone
Description: In the first week, the starting dose is 2mg/Kg per body weight once a day, taken with food at lunch every day, and subsequently adjusted according to the situation. If the patient's serum potassium is ≤5.0 mEq/L and the patient's serum creatinine is ≤2.5 mg/dL, treatment should be initiated with 25 mg spironolactone once daily. Increased to 100mg after remission. If the results are not obvious in the first month, increase the drug dose to 3mg/Kg.
Study: NCT05920330

Intervention type: OTHER
Group type: OTHER
Intervention: Nasal Plug
Description: Please see the arm description for details.
Study: NCT06192641

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin 3 MG
Description: patients received 3 mg melatonin in capsule or placebo (capsule identical to the treatment, both in color, taste, odor and shape, composed of cellulose and indigestible fiber) (PALMER, 2020). (GOLTZMAN, 2021) for 30 days (Treister-Goltzman; Peleg, 2021) They will be instructed to ingest melatonin once a day, at night, one hour before bed (PALMER, et al. 2020).
Study: NCT05319730

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sacituzumab tirumotecan
Description: 4 mg/kg IV infusion on Days 1, 15, and 29 of each 42-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antihistamine
Description: Administered per product label.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: H2 Receptor Antagonist
Description: Administered per product label.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen (or equivalent)
Description: Administered per product label.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone (or equivalent)
Description: Administered per product label.
Study: NCT06623630

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Standard of care

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciltacabtagene Autoleucel
Description: Standard of care

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total body irradiation
Description: Radiation doses delivered to the entire body
Study: NCT04701242

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ezetimibe 10mg
Description: comparing upfront use of Ezetimibe (added to high intensity statins) after acute myocardial infarction versus selective Ezetimibe initiation to those failing to achieve LDL-C targets when assessed in follow up visit.
Study: NCT06303297

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: REFLEXOLOGY
Description: will receive foot and hand reflexology and stretching. The researcher will administer foot and hand reflexology to the participant for a period of 3 weeks this last for a duration of 10 min on each hand and foot with total duration of 40 minutes. Foot reflexology include general foot massage, including the foot rotation, Achilles stretching, and the foot extension and stretching, will be performed for a minute on each foot. In the right foot, the bottom of the heel will be kept with the left hand, and the metatarsal arch of the same foot will be held with the other hand. Then, the foot will be rotated clockwise and counter clockwise three times each direction. The same technique will be performed on the left foot. On hand lubricated with moisturizer to the dorsal and plantar surface and apply pressure on for 10 minutes. Noninvasive and safe complementary therapy that involves a direct pressure on specific body points connecting specific organs.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: GENERALIZED STRETCHING
Description: will receive Stretching of upper and lower limbs. The stretching program lasts for 3 weeks with 60 min of stretching session 3 times a week. Extension of body include shoulder extension, torso rotation, hip extension, calf stretching (ankle pumps). ten stretches of 30 s each, with 15 s of rest between each stretch
Study: NCT06697405

Intervention type: OTHER
Intervention: Prolonged ≥ 120 minutes
Description: No intervention, regular therapy

Intervention type: OTHER
Intervention: Prolonged ≥ 120 minutes
Description: No intervention, regular therapy
Study: NCT06696716

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ONO-4059
Description: Tirabrutinib is a Bruton's Tyrosine Kinase Inhibitor. Tirabrutinib will be administered orally at a dose of 80 mg once daily after a meal (breakfast, lunch, or dinner).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ONO-4059 placebo
Description: Placebo will be administered orally once daily after a meal (breakfast, lunch, or dinner).
Study: NCT06699030

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Functional fatty acids
Description: Days 1-3: Oral Administration of functional fatty acids Days 4-6: Oral Administration of functional fatty acids

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Days 1-3: Placebo Days 4-6: Oral Administration of functional fatty acids
Study: NCT06712329

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: extracorporeal shock wave therapy
Description: ESWT (Inceler Medical, Modus Focused ESWT, Turkey) was conducted by a single investigator in accordance with a standardised protocol. The patients were positioned prone on the examination table, with the affected limb placed in a supported position. The focused shockwave was applied in a circular motion along the insertion site of the plantar fascia and over the plantar fascia itself. The participants received 1,800 to 2,000 focused shock waves (0.15-0.25 mJ/mm² session with a frequency of 3-4 Hz). The frequency of the pulses was increased in a gradual manner, in accordance with the maximum tolerable degree of pain for each patient. A minimum dose of 1,000 mJ/mm² was administered. The ESWT was conducted in three sessions, with a two-week interval between each session.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prolotherapy
Description: The solution employed for dextrose prolotherapy comprised 1.5 ml of 30% dextrose and 1.5 ml of 0.9% isotonic sodium chloride solution, resulting in a total of 3 ml of 15% dextrose solution. . All procedures were conducted by the same investigator. A dextrose solution was infused into the centre and around the damaged area using a peppering technique. Following the procedure, patients were advised to remain in a supine position with their feet restrained for a period of 15 minutes.. Prolotherapy was repeated on three occasions, with each session occurring at a two-week interval
Study: NCT06713005

Intervention type: PROCEDURE
Group type: OTHER
Intervention: suprascapular nerve block and 4 mins Pulsed radiofreuency application to suprascapular nerve
Description: suprascapular nerve pulsed rf

Intervention type: PROCEDURE
Group type: OTHER
Intervention: suprascapular nerve block and 9 mins Pulsed radiofreuency application to suprascapular nerve
Description: suprascapular nerve block and 4 mins Pulsed radiofreuency application to suprascapular nerve
Study: NCT06731530

Intervention type: DEVICE
Intervention: Pentacam-AXL
Description: Pentacam-AXL (Oculus, Wetzlar, Germany)

Intervention type: DEVICE
Intervention: Pentacam-AXL
Description: Pentacam-AXL (Oculus, Wetzlar, Germany)

Intervention type: DEVICE
Intervention: HD Analyzer
Description: HD Analyzer (Visiometrics, Terassa, Spain, Keeler)
Study: NCT05668884

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Combination of Gemcitabine, Oxaliplatin, Donafenib and Tislelizumab
Description: Combination of Gemcitabine, Oxaliplatin, Donafenib and Tislelizumab every 3 weeks
Study: NCT06341101

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perindopril
Description: In case of side effects Perindopril will be replaced by Valsartan
Study: NCT04882384

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pericapsular Nerve Group Block
Description: This will be a peripheral nerve block.
Study: NCT06378580

Intervention type: DRUG
Intervention: Surufatinib combine immune checkpoint inhibitor
Description: Before drug use demographics, blood markers, pathology information# and enhanced CT features.~Chemotherapy regimens that were combined with surufatinib included AG or FOLFIRINOX regimens. The AG regimen consisted of nab-paclitaxel (125 mg/m2) followed by gemcitabine (1000 mg/m2) on days 1 and 8 every 3 weeks. The FOLFIRINOX regimen included oxalip

Intervention type: DRUG
Intervention: AG/FOLFIRINOX
Description: Before drug use demographics, blood markers, pathology information# and enhanced CT features.~The AG regimen consisted of nab-paclitaxel (125 mg/m2) followed by gemcitabine (1000 mg/m2) on days 1 and 8 every 3 weeks. The FOLFIRINOX regimen included oxaliplatin (85 mg/m2), irinotecan (180 mg/m2), leucovorin (400 mg/m2), and 5-fluorouracil (400 mg/m2 bolus, 2400 mg/m2 continuous intravenous infusion for 46 hours) every 14 days. Both the AG and FOLFIRINOX regimens required completion of 6 cycles or until disease progression or unacceptable toxicity.